- Our view
- Buy
- Price at our call
- ₹ 228.00
- Target
- ₹ 456.00
- Return at close
- +92.11%
- Status
- Target achieved 26 Aug 2026 · closed 30 Sep 2026
- Market cap then
- INR 532 Cr.
Shri Ahimsa Naturals Ltd. extracts and processes natural caffeine and green coffee bean extracts, with sales primarily to export markets. The company note highlights a planned capacity expansion at Sawarda, expected to begin commercial production in Apr’26, alongside low debt and positive operating cash flow. It does not provide a stock recommendation, target price or upside.
About Shri Ahimsa Naturals
Founded in 1990 and based in Jaipur, Rajasthan, Shri Ahimsa Naturals extracts and processes Caffeine Anhydrous Natural and Green Coffee Bean Extracts. It sources crude caffeine from decaffeination plants in Vietnam and Mexico, and uses proprietary processes to turn tea and coffee residues and crude caffeine into finished products. Its products serve food and beverage, nutraceutical, cosmetics and pharmaceutical applications. Existing installed capacity is 270 MTPA for natural caffeine and 200 MTPA for green coffee bean extract.
Investment Rationale
- Capacity expansion: The Sawarda unit is planned to add 700 MTPA of Caffeine Anhydrous Natural, 300 MTPA of Green Coffee Bean Extracts and 63 MTPA of crude caffeine capacity. Commercial production is expected from Apr’26, with utilization planned to increase in phases from FY27.
- Project funding: The project cost is INR 60.7 Cr.; INR 35 Cr. is funded from IPO proceeds and the remaining INR 25.7 Cr. from internal accruals.
- Export-oriented business: Exports made up 91% of FY25 sales, with the US identified as a key market. Management stated that caffeine falls under categories exempt from US tariffs.
- Multiple product applications: FY25 product mix comprised Caffeine Anhydrous Natural at 73%, Green Coffee Bean Extract at 23%, and Herbal Products & Others at 4%. Herbal extracts, currently about 2% of sales and outsourced, are planned to be made in-house using the new capacity.
- Certifications and operating profile: The company holds FSSC 22000 approval and several other certifications listed in the report, supporting sales in 14 countries. FY25 Debt/Equity was 0.00x and CFO/EBITDA was 145.8%.
Products and Markets
Natural caffeine is used in food and beverages, nutraceuticals, cosmetics and pharma. Green Coffee Bean Extract is derived from crude caffeine and unroasted coffee beans and is used in nutraceuticals, supplements and functional beverages. Herbal products include extracts such as Senna Leaf, Ashwagandha, Bacopa Monnieri, Turmeric and Garcinia. In FY25, domestic sales were 9% and exports were 91%; exports were made through direct orders, deemed exports and third-party exports.
Shri Ahimsa Naturals Key Financials
| Particulars | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenues | 58 | 104 | 78 | 96 |
| % Y-o-Y | 79.3% | (24.9%) | 22.9% | |
| Gross Mar % | 59.0% | 68.5% | 60.6% | 51.4% |
| EBITDA % | 29.6% | 48.3% | 34.3% | 31.7% |
| PAT % | 18.7% | 36.0% | 23.8% | 22.4% |
| CFO/EBITDA | 83.8% | 40.2% | 21.3% | 145.8% |
| Debt/Equity | 0.24x | 0.05x | 0.16x | 0.00x |
| NWC (Days) | 50 | 76 | 180 | 199 |
Revenue rose to 96 in FY25 after declining to 78 in FY24. The table also shows higher net working capital, at 199 days in FY25.
Industry Context
The report describes dosage precision and purity as important for caffeine applications in beverages, pharma and dietary supplements. It cites a Caffeine Anhydrous market value of $622 Mn. in 2023 and an expected $ 881.5 Mn. by 2030, with CAGR of 6.88% during 2024-30. It also cites a Green Coffee Bean Extract market value of $281 Mn. in 2023 and an expected $ 417 Mn. by 2033, with CAGR of 4%.
Management
The report states that the promoters have three decades of experience in caffeine processing and established customer and supplier relationships. Founder Nemi Chand Jain is Chairman & Managing Director. Amit Kumar Jain is Promoter, Whole Time Director & CFO, and Dipak Kumar Jain is Whole Time Director; both have been associated with the company since 2004.
Key Risks
- Supplier concentration: The top supplier accounted for 73.2% of purchases in FY24, and the top 5 suppliers accounted for 95.5%. The report notes that supplier risk is likely to remain given the nature of the product segment.
- Customer concentration: The top customer represented 65.9% of FY24 sales and the top 5 customers represented 84.9%. Management has stated that it plans to diversify both customer and supplier bases.
- Raw-material and pricing volatility: The report notes a 48% rise in crude caffeine purchase price and volatility in finished-product realizations.
- Uneven demand and sales: The report attributes lower natural caffeine sales to delays in key raw-material deliveries and lower Green Coffee Bean Extract sales to weaker customer demand.
Peer Comparison
The report states that, as per the RHP, there are no listed companies engaged in a similar business.
Our View
The company note focuses on the proposed Sawarda expansion, export-led sales and low FY25 leverage, while also highlighting concentrated suppliers and customers and volatility in input costs and realizations. It provides no stock recommendation, target price or upside.
Standard disclosures:
- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
- Nature of financial interest in subject company, if any –Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
- We or our Associates or Research Analyst are engaged in market making of subject company – No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.
Regulatory disclosures:
Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com| Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In
Rating rationale:
Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.
- Buy:> 15%
- Hold: -5% to 15%
- Reduce: -15% to -5%
- Sell: <-15%